Certificate of Analysis
Independent laboratory testing confirms purity and composition of this research compound.
ENDO PASSED
Compound Specifications
| Form | Lyophilized powder |
| Vial size | 5 mg |
| Kit size | 10 vials per kit |
| Purity | ≥99% (HPLC verified) |
| Mass confirmation | ESI-MS confirmed |
| Heavy metals | <10 ppm (ICP-MS) |
| Endotoxin | <1.0 EU/mg (LAL) |
| Residual moisture | <5.0% (Karl Fischer) |
| Storage — lyophilized | −20°C, protected from light |
| Lyophilized stability | 24 months from manufacture |
| Reconstitution | Bacteriostatic water for injection |
| Storage — reconstituted | 4°C, use within 28 days |
| Packaging | Sterile glass vial · rubber stopper · aluminium crimp cap |
What Is Semaglutide?
Semaglutide is a synthetic GLP-1 receptor agonist peptide with 94% sequence homology to endogenous human GLP-1(7-37). It incorporates two key structural modifications: a C18 fatty di-acid linked via a spacer to Lys²⁶, and a substitution of Aib (α-aminoisobutyric acid) at position 8 to resist DPP-4 cleavage. These modifications extend plasma half-life to approximately 7 days, enabling once-weekly dosing in clinical settings.
Semaglutide is the active compound in Ozempic (injectable, metabolic indication) and Wegovy (injectable, weight management indication) from Novo Nordisk, and Rybelsus (oral formulation). It is the most clinically validated GLP-1 agonist and serves as the reference compound for GLP-1 receptor biology research, with extensive published literature covering energy homeostasis, beta-cell function, neuroinflammation, and cardiovascular endpoints.
Research Overview
| Molecular formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular weight | 4,113.58 g/mol |
| Receptor target | GLP-1R (agonist; ~94% homology to native GLP-1) |
| Half-life | ~7 days (albumin-binding via C18 fatty acid conjugate) |
| Primary research focus | Metabolic regulation, beta-cell function, appetite signalling |
| Secondary research focus | Neuroinflammation, NASH/NAFLD, cardiovascular risk markers |
| Resistance to degradation | Aib-8 substitution blocks DPP-4 cleavage at position 2 |
| Development / approval | Novo Nordisk — FDA approved (Ozempic 2017, Wegovy 2021) |
Research Notes
Semaglutide’s role as the benchmark GLP-1 agonist makes it central to incretin biology research. In preclinical models, GLP-1R activation by semaglutide reduces food intake by modulating hypothalamic appetite circuits (arcuate nucleus NPY/AgRP neurons) and activating area postrema satiety signalling. Beyond metabolic endpoints, recent research has identified GLP-1 receptors in microglia and astrocytes, with semaglutide reducing neuroinflammatory cytokine output in LPS-stimulated models. SUSTAIN and STEP trial data provide the most comprehensive human dataset for any GLP-1 compound — a useful reference baseline for interpreting preclinical findings. Beta-cell protection and potential beta-cell proliferation effects in rodent models remain an active area of mechanistic inquiry.
Frequently Asked Questions
- How does semaglutide compare to liraglutide in research models?
- Liraglutide (C16 fatty acid conjugate) has a ~13-hour half-life; semaglutide’s C18 di-acid with PEG spacer extends this to ~7 days. Semaglutide achieves substantially greater receptor activation per weekly dosing interval. For in vitro receptor binding assays, both are used as reference agonists, but semaglutide’s structural complexity requires more careful aggregation monitoring in solution.
- What solvent should be used for reconstitution?
- Bacteriostatic water is standard. Given semaglutide’s fatty acid conjugate, gentle agitation (not vortexing) is recommended to avoid aggregation. Stock solutions should be prepared fresh or stored at 4°C for no more than 28 days. Freeze-thaw cycles significantly degrade bioactivity.
- Is research-grade semaglutide structurally identical to pharmaceutical semaglutide?
- Research-grade semaglutide is synthesised to match the published sequence and modifications of pharmaceutical semaglutide. Purity and characterisation data (HPLC, ESI-MS) are supplied with every lot. Researchers should confirm structural identity via mass spectrometry before use in mechanistic studies.
What is Semaglutide used for in research?
Semaglutide is studied as a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid conjugation, making it one of the most pharmacokinetically stable GLP-1R agonists available for research. Studies examine its effects on beta-cell function, insulin secretion, appetite regulation, and gastric emptying in metabolic models. Secondary research areas include neuroinflammation, NASH/NAFLD, and cardiovascular risk marker modulation.
Is Semaglutide available as lyophilized vials?
Yes. BIOHACKER’s Semaglutide is supplied as lyophilized powder in individual vials. Each vial contains 5 mg of research-grade Semaglutide at ≥99% HPLC purity. Reconstitute with bacteriostatic water before use. For research purposes only.
What purity is BIOHACKER’s Semaglutide?
≥99% by HPLC, with ESI-MS mass confirmation and endotoxin testing to USP <85> standards. Full Certificate of Analysis is available on the COA page and traceable by batch number.
Is this for human consumption?
No. Semaglutide from BIOHACKER is sold strictly for in vitro research and laboratory use. It is not intended for human or veterinary use and is not a dietary supplement or pharmaceutical product.
Ready to order? Add to Cart — $300
Research Use Only. This product is intended for in-vitro laboratory research purposes only. Not for human consumption, clinical use, veterinary use, or food/drug manufacturing. Not evaluated or approved by the FDA or any regulatory authority. Handle with appropriate laboratory precautions. Keep out of reach of children.
Reviews
There are no reviews yet.